Focused On-demand Library for Glutamate receptor 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for receptors.

Fig. 1. The sreening workflow of Receptor.AI

It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P42261

UPID:

GRIA1_HUMAN

Alternative names:

AMPA-selective glutamate receptor 1; GluR-A; GluR-K1; Glutamate receptor ionotropic, AMPA 1

Alternative UPACC:

P42261; B7Z2S0; B7Z2W8; B7Z3F6; B7Z9G9; D3DQI4; E7ESV8; Q2NKM6

Background:

Glutamate receptor 1, known by alternative names such as AMPA-selective glutamate receptor 1, GluR-A, GluR-K1, and Glutamate receptor ionotropic, AMPA 1, plays a pivotal role in the central nervous system. It functions as an ionotropic glutamate receptor, where L-glutamate, an excitatory neurotransmitter, induces a conformation change leading to cation channel opening. This process converts chemical signals to electrical impulses, essential for synaptic transmission.

Therapeutic significance:

Glutamate receptor 1 is implicated in Intellectual developmental disorder, autosomal dominant 67, and Intellectual developmental disorder, autosomal recessive 76, both characterized by developmental delays and impaired intellectual development. Understanding the role of Glutamate receptor 1 could open doors to potential therapeutic strategies for these disorders.